Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

Name: Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
Author: Heudel, Pierre

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial. — المؤلف: Heudel, Pierre — JAMA oncology 20220725

المؤلف: Heudel, Pierre
النشر: JAMA oncology 20220725
الوصف: 1001-1009 p.
الموضوعات: Aged؛ Anastrozole؛ Antineoplastic Combined Chemotherapy Protocols؛ Benzamides؛ Breast Neoplasms؛ Endometrial Neoplasms؛ Female؛ Humans